Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Efficacy of Antihypertensive Drugs and miR-632 Inhibition on Parietal Remodeling in a Model of Marfan Thoracic Aortic Aneurysm.

Biomolecules·2026
Same author

Case Report: E-cadherin and Vimentin expression in advanced-stage pancreatic ductal adenocarcinoma tissue and circulating tumor cells: preliminary results from a pilot study.

Frontiers in oncology·2026
Same author

Merkel Cell Polyomavirus and DNA Damage Response (DDR): Transcriptional Analysis of DDR Pathways in the Context of Merkel Cell Carcinoma.

Cancers·2026
Same author

Potential Antifungal Activity of Retinoids Against Non-<i>albicans Candida</i> Species.

Microorganisms·2026
Same author

Tuberculosis-associated IRIS in a young non-HIV patient undergoing TNF-α blockade for ankylosis spondylitis: a rare case report from Italy.

Journal of clinical tuberculosis and other mycobacterial diseases·2026
Same author

Clusters of Anthropometric Features in Colorectal Cancer Patients with Synchronous Metastases and Their Association with Overall Survival and RAS Mutation.

Journal of gastrointestinal cancer·2026
Same journal

Corrigendum to 'The Ninth Edition Staging Project Publications' [Journal of Thoracic Oncology (2022-2024)].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC: The ACTIVE Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Brief Report: Proposed clinical trial guidelines based on clinicopathological heterogeneity of metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

ctDNA based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistance.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Cardiac sarcomas: an update.

Augusto Orlandi1, Amedeo Ferlosio, Mario Roselli

  • 1Department of Anatomic Pathology, Tor Vergata University, via Montpellier, Rome, Italy. orlandi@uniroma2.it

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|July 24, 2010
PubMed
Summary
This summary is machine-generated.

Primary cardiac sarcomas are rare tumors. Diagnosis requires tissue sampling, and treatment involves surgery, radiation, and chemotherapy, but prognosis remains poor.

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jun 10, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

  • Cardiology
  • Oncology
  • Pathology

Background:

  • Primary cardiac sarcomas are rare, comprising 20% of primary cardiac tumors.
  • Symptoms vary based on cardiac chambers and structures affected.
  • Transthoracic echocardiography is a key diagnostic tool for cardiac masses.

Purpose of the Study:

  • To review the diagnosis, classification, treatment, and prognosis of primary cardiac sarcomas.
  • To highlight the challenges in diagnosing and managing these rare tumors.
  • To discuss factors influencing the clinical course and survival.

Main Methods:

  • Review of current literature on cardiac sarcomas.
  • Analysis of diagnostic techniques, including histology and ancillary methods.
  • Summary of therapeutic strategies and prognostic indicators.

Main Results:

  • Angiosarcoma is the most common malignant heart tumor with differentiation.
  • Undifferentiated sarcomas constitute one-third of cardiac sarcomas.
  • Prognosis is generally poor, with mean survival of 9.6–16.5 months.

Conclusions:

  • Cardiac sarcoma diagnosis necessitates adequate tissue sampling and advanced techniques.
  • Treatment involves surgical resection, radiotherapy, and chemotherapy (anthracyclines, ifosfamide, taxanes).
  • Favorable prognostic factors include left atrium location, low histologic grade, and absence of metastasis.